HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Beauty care manufacturer obtains three-year, $300 mil. revolving credit facility with Bank of America (administrative agent), Bank One, LaSalle Bank and Citibank, firm announces Sept. 10. Credit facility will be used for general corporate purposes, including possible acquisitions, although firm notes it has "no plans" to draw on facility in near future. Melrose Park, Ill. company recently noted its interest in acquisitions, citing one possibility worth more than $100 mil. (1"The Rose Sheet" April 29, 2002, p. 4). New credit arrangement replaces five-year, $250 mil. facility that expired Sept. 10...

You may also be interested in...


Beauty care manufacturer extends its $300 mil. revolving credit agreement with group of banks from three to five years, firm announces Sept. 2. Agreement between Alberto and Bank of America, Citibank, Bank One, LaSalle Bank, William Street Commitment Corporation and Svenska Handelsbanken was signed Aug. 31. Company notes amended facility will be used for "general corporate purposes, including possible acquisitions," but added it has no plans to draw from it in the near future. Alberto obtained the $300 mil. facility in 2002 (1"The Rose Sheet" Sept. 16, 2002, In Brief)...

St. Ives Daily Cleansing Cloths Launching With TV, Print Ads

Alberto-Culver will promote the exfoliating benefits of its new St. Ives cleansing cloths as a point of difference with other facial cloths in the market, according to VP-Skin Care Jim Gonedes

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts